This Study performs unique rapid on-site measurement using patient whole blood and positions Company to move forward with multiple initiatives ACTON, Mass., Jan. 13, 2022 (GLOBE NEWSWIRE) -- Bluejay ...
ACTON, Mass., May 19, 2023 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical technology company developing rapid diagnostics on its Symphony platform ...
This Study performs unique rapid on-site measurements of interleukin-6 (IL-6) and positions Company to move forward with multiple initiatives. ACTON, Mass., Dec. 27, 2023 (GLOBE NEWSWIRE) -- Bluejay ...
RARITAN, N.J., July 22, 2021 /PRNewswire/ — Ortho Clinical Diagnostics (Nasdaq: OCDX), one of the world’s largest pure-play in vitro diagnostics companies, today announced its VITROS (R) ...
The company’s first product candidate is an IL-6 Test for sepsis. The company emphasized that the Symphony System remains under development and subject to further validation and regulatory review.
(RTTNews) - Swiss drug maker Roche (RHHBY) announced Thursday that the U.S. Food and Drug Administration has issued an Emergency Use Authorisation or EUA for the Elecsys IL-6 test to help in ...
ACTON, Mass., Dec. 29, 2025 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”) announced that it has completed commercial-scale production of both polyclonal and ...
This trial is crucial for the further development of its Symphony IL-6 test for sepsis detection. Additionally, Bluejay Diagnostics has successfully closed a $4.5 million private placement, selling ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results